Amyotrophic lateral sclerosis (ALS) and hereditary spastic paraplegia (HSP) are 2 distinctive degenerative motor neuron diseases (MNDs). HSP is a slow progressing disease usually starting in childhood or young adulthood. Its common feature is the degeneration of the upper motor neurons leading to weakness and spasticity restricted to the lower limbs. In ALS, and some complex forms of HSP, the lower motor neurons are also affected. ALS leads to a mostly rapidly progressive paralysis of the 4 limbs, bulbar area, and respiratory muscles, typically beginning in the sixth to seventh decade of life, with a median survival of 2--4 years after onset of disease. Disease progression is slower in HSP and is dependent of associated clinical signs. Homozygous nullimorphic deletion/frameshift mutation or compound heterozygous splice site/missense mutations in endoplasmic reticulum lipid raft-associated protein 2 (*ERLIN2*) have been identified as a cause of SPG18, a form of HSP, juvenile primary lateral sclerosis, and a neurologic disorder termed "intellectual disability, motor dysfunction, and joint contractures (IDMDC)" all being neurodegenerative diseases of the upper motor neuron with onset in early childhood.^[@R1][@R2][@R3]^ A dominant form of pure HSP was recently reported to be caused by a heterozygous mutation in *ERLIN2*, which underlines the complexity of the *ERLIN2* mutation in spastic paraplegia (SP) phenotype.^[@R4]^ Here, we described *ERLIN2* mutations segregating with MND in 2 pedigrees affecting patients with HSP evolving to rapid progressive ALS.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

All patients signed a consent form for the genetic research. Protocols were approved by the Medical Research Ethics Committee of "Assistance Publique Hôpitaux de Paris." The diagnosis of ALS and SP was based on the published criteria as previously described.^[@R5]^

Genetic screening {#s1-2}
-----------------

This patient cohort (including 200 familial and 60 sporadic cases) were screened for *C9orf72*.^[@R5]^ Then whole exome sequencing was performed using classical procedures. Exons were captured on the genomic DNA using the SureSelect Clinical Research Exome 50Mb kit (Agilent), followed by massive parallel sequencing on a Hiseq 2000 sequencer (Illumina) at Integragen (Evry, France). The Burrows-Wheeler algorithm was used to align the 100 bp length paired-end reads to the hg38 version of the human genome (Ensembl); variants were called using the Genome Analysis Toolkit software. Data were imported into the SIRIUS ([sirius.integragen.com](https://sirius.integragen.com)) database for further analysis. This database was interrogated for 30 ALS-related genes (including *ALS2, ANG, ANXA11, CCNF, CHCHD10, DAO, DCTN1, FIG4, FUS, GLE1, GLT8D1, HNRNPA1, HNRNPA2B1, KIF5A, MATR3, NEK1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SQSTM1, SS18L1, TARDBP, TBK1, TIA1, TUBA4A, UBQLN2, VAPB*, and *VCP*) and 70 SP genes^[@R6]^ to select variants with a minor allele frequency \<0.005% in Single Nucleotide Polymorphism Database, HapMap, 1000 Genomes, Exome Variant Server, and gnomAD databases. *ERLIN2* variants were validated using Sanger analysis with BigDye chemistry as recommended by the supplier (Applied Biosystems). Segregation of the identified variant with the disease was checked for all family members with available DNA.

Data availability {#s1-3}
-----------------

Anonymized data are available from the corresponding author upon reasonable request.

Clinical findings {#s1-4}
-----------------

In ALSSP1 pedigree, 2 second-degree cousins were diagnosed with ALS according to the Awaji criteria at ages 57 years (IV1) and 65 years (IV2), respectively ([figure, A](#F1){ref-type="fig"}). The site of onset of lower MND was either the upper limbs (UL) for IV1 or bulbar and UL (IV2). Death occurred 12--18 months later due to restrictive respiratory insufficiency. Both had SP beginning 20 (IV2) to 32 years (IV1) before ALS onset. IV3 presented HSP from age 32 years, without signs of peripheral motor neuron dysfunction to date. In ALSSP2 pedigree, 2 brothers developed definite ALS at ages 54 (III2) and 59 (III4) years, respectively, both of bulbar and UL onset, occurring 38--39 years after HSP diagnosis ([figure, B](#F1){ref-type="fig"}). ALS disease was rapidly progressive with an ALS Functional Rating Scale-Revised (ALSFRS-R) score ratio^[@R8]^ of 2.25 (III2) and 3.66 (III4), respectively ([table 1](#T1){ref-type="table"}). Their sister had mental retardation and typical HSP starting at age 15 years. An apparently sporadic subject developed SP at age 45 years, and then converted to ALS of UL and bulbar onset at age 66 years. ALS disease was also rapid progressive (ALSFRS-R ratio 1.41) with death occurring 20 months after conversion to ALS. A last patient, previously healthy, developed typical spinal ALS of UL onset at age 45 years. During disease course, notorious spasticity of the lower limbs was noted. He died 4 years after disease onset. His mother had died of bulbar ALS 5 years after first symptom onset (ALSSP3).

![Identification of *ERLIN2* mutations in patients with ALS\
Pedigrees of the ALSSP1 and ALSSP2 families with the heterozygous V168M (A) and homozygous D300V (B) mutations. Arrows indicate index patients. When available, the age at death (in brackets) is indicated above the symbol representing the patients. Black fill: ALS case; black half fill: SP case. The genotypes are indicated using a single letter amino acid code below the index case and some relatives for whom DNA was available (m/+: heterozygous, m/m: homozygous). (C) Representation of Erlin-2 protein domains with the position of the amino acid substitutions previously reported in spastic paraplegia (gray), juvenile primary lateral sclerosis (purple), intellectual disability, motor dysfunction, and multiple joint contractures (black). Mutations identified in patients with ALS in the present study are in red. Full underline, homozygous mutations; dotted line, compound heterozygous mutation. SPFH, stomatins, prohibitins, flotillins, and HflK/C domain (green); Oligomerization domain (blue); hydro, hydrophobic patch (orange). Data are compiled from [@R1], [@R2], [@R3], [@R4], [@R6], [@R7]. (D) Part of chromatograms showing the N125S (exon 6), the V168M (exon 8), the D300V, and the A309V (exon 12) variants pointed by an arrow (in patients) and the corresponding normal sequences (in control). (E) Sequence alignments of part of the Erlin-2 amino acids from diverse species using MultAlin web site. The positions of the Asn125, Val168, Asp300, and Ala309 (pointed by an arrow) are in red. Sequences used include *Homo sapiens* (NP_009106.1), *Pongo abelii* (NP_001126372.1), *Mus musculus* (NP_705820.1), *Rattus norvegicus* (NP_001099558.1), *Bos taurus* (NP_001040041.1), *Gallus gallus* (XP_424380.1), *Xenopus tropicalis* (NP_001016719.1), and *Danio rerio* (NP_001121887.1). Human Erlin-1 amino acid sequence is also indicated in blue (NP_001094096.1). ALS = amyotrophic lateral sclerosis; SP = spastic paraplegia.](NG2019011064f1){#F1}

###### 

Clinical features of patients harboring *ERLIN2* mutations
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Genetic findings {#s1-5}
----------------

A heterozygous *ERLIN2* c.502G\>A, p.Val168Met (V168M) mutation was found in ALSSP1 pedigree, cosegregating with disease and accounting for the autosomal dominant form of MND in this family. In pedigree ALSSP2, a homozygous *ERLIN2* c.899A\>T, p.Asp300Val (D300V) mutation was recessively transmitted. Another variant c.374A\>G, p.Asn125Ser (N125S) was found in the isolated case. A last *ERLIN2* variant c.926C\>T, p.Ala309Val (A309V) was identified in the ALSSP3 familial index case ([figure, C and D](#F1){ref-type="fig"}).

No other variant in the main ALS- or HSP-related genes was identified in these individuals. All but 1 variant were predicted to be deleterious by 5 in silico algorithms ([table 2](#T2){ref-type="table"}). As A309V variant was predicted to be less pathogenic than the other ones and affects a less conserved amino acid across species and paralogs, it could rather be considered as a variant of unknown significance. In contrast, the 2 other variants dominantly transmitted (N125S and V168M) are located in the stomatins, prohibitins, flotillins and HflK/C domain of Erlin-2 protein, affect residues that are conserved up to the zebrafish in Erlin-2 sequence, are conserved in human Erlin-1 sequence too ([figure, E](#F1){ref-type="fig"}), and remain absent from control databases, suggesting that they are highly pathogenic.

###### 

Pathogenicity prediction tests for *ERLIN2* mutations
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Discussion {#s2}
==========

A genetic overlap has been previously described for various MNDs: recessive mutations in *ALS2* and *SPG11* have been identified in patients with HSP or slowly progressive juvenile-onset ALS.^[@R9]^ Recessive mutations in *SPG11* are also responsible for CMT2.^[@R9]^ Dominant mutations in *KIF5A* can lead to HSP, CMT2, or ALS depending on the protein domain they affect.^[@R10]^ Here, we report the identification of *ERLIN2* mutations in patients with a primarily SP evolving to severe ALS phenotype. It is to note that 3 of the 12 patients reported with IDMDC died between ages 18 and 23 years, albeit the cause of these premature deaths was not detailed.^[@R3]^ Among the mutations we identified, 3 (N125S, V168M, and A309V) are novel, and the last one (D300V) was already identified in a consanguineous family of Portuguese origin with pure HSP.^[@R6]^ These mutations segregated with the disease in a dominant (V168M) or recessive (D300V) manner underlying the complexity of *ERLIN2* mutation inheritance along the MND spectrum. Such an SP to ALS switch has recently been described for the dominant X-linked *UBQLN2* ALS-related gene,^[@R5]^ and our present results added *ERLIN2* as a candidate gene for this form of MND. The mean disease duration before conversion of the phenotype ranged from 20 to 45 years and seemed to be increased when SP disease onset occured earlier. The severe prognosis of ALS complicates the genetic counseling delivered to these SP families. Some affected members of the families we described remain to date with SP phenotype, suggesting that modifier genes could also intervene in the worsening of the motor phenotype.

Erlin-2 is involved in the endoplasmic reticulum--associated degradation pathway of inositol 1,4,5-trisphosphate receptors (IP3Rs) through ubiquitination and the regulation of cellular cholesterol homeostasis. The homozygous null allele identified in patients with SPG18 suggests that the loss of Erlin-2 function was pathogenic through persistent activation of IP3R and neuronal channels,^[@R1]^ and whether this mechanism is also at work in ALS phenotype remains to be investigated.
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ALS

:   amyotrophic lateral sclerosis

IDMDC

:   intellectual disability, motor dysfunction, and joint contractures

HSP

:   hereditary spastic paraplegia

MND

:   motor neuron disease

SP

:   spastic paraplegia

UL

:   upper limb

VUS

:   variant of unknown significance
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